Introduction: A Critical Shift in Infection Control
The global battle against antimicrobial resistance (AMR) has reached a critical juncture. As pathogens evolve to outpace our most potent pharmaceutical defenses, the National Health Service (NHS) in the United Kingdom is spearheading a transformative research project that could redefine how hospitals manage one of their most persistent threats: carbapenemase-producing Enterobacterales (CPE).
The Fleming Initiative—a collaborative powerhouse between Imperial College London and Imperial College Healthcare NHS Trust—has officially joined forces with Cepheid, a subsidiary of Danaher, to launch the "TRACE-CPE" study. This ambitious two-and-a-half-year investigation is designed to determine if shifting from traditional laboratory culture methods to rapid molecular screening can fundamentally alter the trajectory of hospital-acquired infections, optimize resource allocation, and provide the evidence base required for new national health policies.
The Threat of CPE: Why Speed Matters
CPE represents a significant challenge in modern medicine. These bacteria have developed the ability to produce enzymes known as carbapenemases, which render carbapenems—often considered antibiotics of last resort—ineffective. The World Health Organization (WHO) classifies these organisms as "critical-priority pathogens," reflecting their ability to cause severe, life-threatening infections and their propensity to spread rapidly within healthcare settings.
In the UK, the situation is increasingly urgent. Data from the UK Health Security Agency (UKHSA) indicates that the incidence of carbapenemase-producing organisms in England more than doubled between 2021 and 2023. When undetected, these bacteria can circulate silently through hospital wards, leading to outbreaks that result in extended patient stays, increased mortality rates, and significant financial strain on the NHS due to emergency ward closures and the disruption of elective care pathways.
Study Objectives: Comparing Methods and Outcomes
At the heart of the TRACE-CPE study is a direct comparison between established diagnostic protocols and emerging molecular technologies.
The Traditional Bottleneck
Standard culture-based screening methods, while reliable, are inherently slow. Culturing a sample typically requires approximately 48 hours to yield actionable results. In a busy acute-care environment, two days is a lifetime; patients may be moved, surgeries performed, and cross-contamination may occur long before clinicians are alerted to the presence of a CPE-positive patient.
The Molecular Advantage
The study will evaluate rapid molecular diagnostic tests, which utilize polymerase chain reaction (PCR) technology to identify the genetic signatures of CPE. These tools can deliver clinical results in approximately one hour. The research team aims to measure not just the speed of detection, but the downstream clinical impacts:
- Infection Transmission: Does faster identification lead to earlier isolation and reduced ward-level transmission?
- Clinical Practice: How do rapid results change the behavior of frontline staff regarding patient placement and antibiotic stewardship?
- Patient Experience: How does earlier knowledge of status affect the psychological and physical journey of the patient?
- Health Economics: What are the system-level cost-benefits when accounting for the prevention of outbreaks versus the increased cost of molecular testing?
Chronology and Scope
The TRACE-CPE project is structured as a longitudinal study spanning 30 months, ensuring that the data collected is robust enough to influence long-term policy.
- Phase 1 (Preparation and Baseline): The initial months are focused on integrating diagnostic equipment into the clinical workflows of the participating institutions: Imperial College Healthcare NHS Trust and Guy’s and St Thomas’ NHS Foundation Trust.
- Phase 2 (Data Collection): Over the majority of the study, researchers will monitor the impact of rapid testing on diverse patient populations. By drawing from two major NHS institutions, the study ensures that its findings are representative of the complex, multi-layered environment of modern acute care.
- Phase 3 (Analysis and Synthesis): The final stages will involve synthesizing the data to assess system-level productivity, patient outcomes, and the feasibility of a national rollout.
The study is being led by Dr. Jonathan Otter, Director of Infection Prevention and Control at Guy’s and St Thomas’ NHS Foundation Trust, alongside Dr. Damien Ming, a research fellow with the Fleming Initiative. Their combined expertise in clinical microbiology and public health policy provides a balanced perspective on both the technical and practical challenges of implementation.
Official Responses and Strategic Vision
The partnership with Cepheid is strategic, aiming to bridge the gap between diagnostic innovation and practical healthcare delivery. Anne Beaubrun, Vice-President of Value and Access at Cepheid, emphasized that the project is about more than just the accuracy of a test; it is about the "systems-level" impact of diagnostics.
"Through our partnership with the Fleming Initiative, we are focused on generating the kind of evidence that determines whether diagnostics actually change outcomes inside the systems delivering care," Beaubrun stated. She noted that the study evaluates how these tools integrate into clinical workflows, generating evidence to support the UK’s National Action Plan (NAP) on AMR and the broader goals of the NHS 10-year plan.
By evaluating the integration of these tools, the research aims to provide a clear roadmap for hospital leaders. The goal is to move away from reactive infection control and toward a proactive, evidence-based strategy that aligns with the long-term vision for a more efficient, technology-driven NHS.
Implications for Healthcare Policy and Practice
The potential implications of the TRACE-CPE study extend far beyond the walls of the participating hospitals. If the study demonstrates that rapid molecular screening significantly reduces transmission rates and improves patient outcomes, it will provide the evidence necessary for the NHS to revise its national screening guidelines.
Strengthening Antimicrobial Stewardship (AMS)
Rapid diagnostics are a cornerstone of effective stewardship. When clinicians have fast, accurate information, they can tailor antibiotic therapy more precisely, avoiding the broad-spectrum "shotgun" approach that often drives the development of resistance. By minimizing the use of unnecessary last-resort antibiotics, hospitals can preserve these drugs for the patients who truly need them.
Economic and Systemic Resilience
The economic burden of CPE is multifaceted. Beyond the direct costs of testing, the indirect costs—ward closures, increased nursing hours for contact tracing, and prolonged hospitalizations—place an enormous strain on NHS resources. A successful outcome from the TRACE-CPE study could demonstrate that the higher upfront cost of molecular diagnostic kits is offset by the massive savings generated by preventing outbreaks.
A Model for Future Innovation
The collaborative nature of this study—linking academic excellence, NHS operational expertise, and private-sector innovation—serves as a model for future research into infectious diseases. As seen with Cepheid’s recent US FDA clearance for its Xpert GI Panel, the rapid evolution of diagnostic technology is accelerating. TRACE-CPE acts as a vital bridge, ensuring that these technological leaps are grounded in the realities of patient care and clinical necessity.
Conclusion: Setting the Standard for the Future
The TRACE-CPE study is a landmark endeavor in the fight against antimicrobial resistance. By rigorously assessing the integration of rapid molecular diagnostics into the complex, high-pressure environment of the NHS, the Fleming Initiative and Cepheid are doing more than just testing a product; they are testing a paradigm shift.
As the findings emerge over the next two years, they will likely provide the definitive evidence required by policymakers, hospital executives, and clinicians to decide how to deploy resources in the ongoing war against drug-resistant bacteria. In an era where the efficacy of our antibiotic arsenal is dwindling, the ability to act quickly is not just a technological advantage—it is a clinical imperative. If TRACE-CPE proves successful, it will not only save lives and hospital resources but will also cement the UK’s position at the forefront of global efforts to contain the silent pandemic of antimicrobial resistance.
About the Author
